National Donor Day 2026: Build trustworthy, accurate pathways for organ, eye, tissue, blood, platelet, and marrow donation

Deceased organ and tissue donation can unfold during an intense end-of-life period. Intensive care teams remain responsible for clinical care. Qualified donation professionals complete the applicable evaluation and authorization processes. Leaders must ensure that clinical staff know when to notify the appropriate organization, what information can be transferred, who may approach a family, and how medical uncertainty is explained. A policy that exists only in a binder is not a reliable pathway.

A 2026 scoping review of 28 papers identified seven recurring challenges for intensive care nurses: direct patient care, care for next of kin, understanding brainstem death, ethical challenges, emotional demands, communication, and organizational conditions. Most included studies were qualitative, so the review maps experience rather than estimating the frequency of each problem. It supports training, protocols, debriefing, and accessible expert support, but it does not establish that one intervention will raise authorization rates in every institution.⁴

The family approach itself is the most studied and least standardized step. A systematic review of 92 studies described the experience of professionals who approach families as a paradox of negotiating the boundary between life and death, shaped by organizational and personal factors. Training and education improved staff experience, but the quantitative studies in the review did not show a strong association between donation training and higher consent rates, and the variety of approaches helps explain why no uniform model exists across settings. Interviews with 30 organ procurement coordinators in Türkiye identified five recurring barriers to family consent: religion, uncertainty about the wishes of the deceased, a desire to choose recipients, family dynamics, and folklore. These findings are context specific. Their value is explanatory, not universal measurement.^{8, 11}

Family support cannot be reduced to wording on a script. A mixed-methods study of 594 pediatric cases in the United Kingdom found that parents described concerns about donation changing end-of-life care, cultural or religious beliefs, and the need for surgery. Facilitating factors included altruism, prior knowledge, and the possibility of a positive legacy. The study also reported associations between consent and child age, race, and donation pathway. Leaders should not use these findings to profile an individual family or predict a decision. They should use them to prepare for varied concerns and to review whether every family receives understandable, respectful, and individualized support.⁷

Legislation does not remove that work. After England adopted deemed consent in 2020, a qualitative study of 103 participants representing 83 potential donation cases found that families fully supported donation in 37% of cases, supported retrieval of only some organs, tissues, or procedures in 49%, and declined completely in 13%. Families were often confused about deemed consent and about their own role, and many questioned whether their relative would have wanted surgery. The sample was purposive rather than representative, so the percentages describe the interviewed cases, not national practice. The lesson for executives is that a policy change shifts the conversation but does not replace prepared, well-supported clinicians at the bedside.¹³

Living donation requires a particularly strong separation between the potential donor’s interests and the recipient’s needs. Evaluation should protect voluntariness, informed consent, medical and psychosocial suitability, privacy, and freedom to withdraw. Leaders should ask whether transportation, time away from work, caregiving duties, language, digital access, and financial strain make the process easier for some people than others. A program may be clinically excellent while still imposing burdens that exclude or pressure particular groups.

A 2026 mixed-methods study from one tertiary center in North India reviewed 1,171 live kidney-donor records and interviewed 92 women. Seventy-nine percent of donors in the center’s cohort were women. The interviews described motivations linked to family roles, economic dependence, perceived social position, and altruism. The setting and social context are specific, so the percentages cannot be generalized to U.S. programs. The study is valuable because it demonstrates why a simple donor count can hide questions about autonomy and gendered expectations.⁵

A qualitative pilot study with 14 ethnically diverse former living kidney donors in the United States found that most experienced outcomes they had not anticipated, including postsurgical complications such as hernia, fatigue lasting 12 weeks or longer, emotional distress, hypertension, and gout, along with difficulty obtaining life insurance. Three participants were erroneously told by primary care providers that they had developed kidney disease because postdonation laboratory values were misread. Participants nonetheless reported no regrets. Small qualitative samples cannot quantify how often each experience occurs. They can reveal domains that a routine postoperative measure may miss. Donor programs should therefore define ownership for psychosocial assessment, financial-navigation referral, primary-care education about postdonation values, adverse-event response, and long-term follow-up.¹⁴

Blood and platelet programs operate on a different time horizon than deceased donation. They depend on recurrent participation, stable collection capacity, donor eligibility, product demand, and responsive scheduling. Health systems may host drives, promote community appointments, provide staff education, or partner with a blood service. Each public message should link to the current accepting service rather than copy eligibility rules that can become outdated or omit an individual consideration.

Donor safety is an operating requirement and a retention strategy. A cross-sectional analysis of donor hemovigilance data reported by 85 blood services to China’s national network from 2020 to 2022 recorded 32,523 adverse donor reactions, 96.8% of them vasovagal, with an overall reported incidence of 12.577 per 1,000 donations as expressed by the authors. Vasovagal reactions were more common among female donors than male donors and far more common among first-time donors (18.536%) than repeat donors (5.819%), and syncope was more frequent at outdoor collection sites and in group drives than at indoor sites and among individual donors. Reporting completeness varies across services, so the figures describe reported events, not a universal risk prediction. They support careful counseling, observation, adverse-event classification, and particular attention to the first-time donor experience.²

Retention also depends on what the organization does after the appointment, including after a deferral. A randomized controlled field trial at 10 Dutch blood donation centers tested two approaches to encourage deferred donors to return: offering an alternative good deed did not significantly increase return, while providing additional information about the deferral did increase whole-blood donor return. The trial was conducted in one national system with its own deferral rules, so effect sizes should not be transferred directly. Its practical message is that explanation is an operating intervention. A deferral delivered without context can end a donor relationship that a clear conversation would have preserved.¹⁷

Digital tools can extend reach, but reach is not the same as readiness or retention. An Austrian regional blood service that built a fully integrated donor app reported 45,000 users 18 months after launch; its digital health questionnaire reduced deferrals by 31.9% compared with the paper form, and digital adopters showed a shorter median donation interval (193 days versus 316 days). Those results describe one service with in-app incentives and cannot separate the app’s effect from the characteristics of donors who chose to adopt it. A South African survey of 2,154 respondents found that 41% believed a donation app would encourage younger people to donate more regularly, a perception rather than an observed behavior. Executives should require any digital campaign or tool to connect with real inventory needs, accurate appointment capacity, an authoritative eligibility route, privacy protection, and measures beyond downloads and clicks.^{15, 18}

Community partnership should shape both access and communication. Qualitative research with voluntary donors and non-donors in South Kivu found that fear shaped decisions at every stage from recruitment to cessation, that the meaning people attached to donation mattered, and that expectations of material or non-material return were high in a context of poverty and limited access to transfusion. Research in Hong Kong and Ireland describes different combinations of knowledge gaps, appointment experience, deferral concerns, representation, historical relationships, and trust. These studies should not be combined into a single global ranking. Together they demonstrate why donor recruitment must be locally designed and why low participation should not be attributed to indifference without examining the system.^{9, 10, 16}

Equity review should be pathway specific. For deceased donation, leaders may examine recognition, referral, family approach, authorization, clinical disposition, and bereavement support. For living donation, review evaluation access, withdrawal protections, financial burden, recovery, and long-term follow-up. For blood and platelets, examine eligibility deferrals, appointment geography, wait time, donor reactions, staff experience, repeat participation, and product use communication. For marrow registries, separate enrollment, contactability, confirmatory testing, availability, donation completion, and donor support.

Stratification must be accompanied by case review and community interpretation. A lower rate can reflect a correct clinical decision, a documentation gap, inaccessible service, lack of trust, an unaddressed cost, or a personal preference. Treating every difference as a deficit in the community can reproduce the problem the analysis is meant to solve. Leaders should define who reviews the data, how small numbers are protected, how community representatives participate, and what evidence is needed before changing practice.

Trust also requires honest limits. Organizations should not imply that registration guarantees donation, that every volunteer will be eligible, that every registry member will match, or that one donated unit or organ has a predetermined result. Communication can honor generosity without using pressure, fear, or simplified “hero” language that obscures risk and uncertainty. Donors, families, and recipients deserve information that remains accurate even when the pathway does not produce the hoped-for outcome.

Registry recruitment is often treated as the primary success measure. That approach can overstate capacity if registered members cannot be reached, no longer understand the commitment, face barriers to confirmatory testing, or decline when contacted. A registry drive should explain that a future match may require additional testing, health evaluation, scheduling, travel or time commitments, and one of more than one possible collection approaches. The exact process belongs to the authoritative registry and clinical team, not to a local awareness page.

A 2025 qualitative study focused on donation-related decision-making among young Black and Hispanic registry members, bringing needed attention to the perspectives of groups that may be underrepresented in some registries. Earlier qualitative work with 76 college students identified knowledge, communication, facilitators, barriers, and perceptions of altruism as influences on both recruitment and retention. The age and settings limit generalization, and the college study is more than a decade old, but the studies support a shift from one-time sign-up messaging to informed readiness and sustained contact.^{12, 21}

Representation has clinical implications because human leukocyte antigen patterns and donor availability differ across populations. An Israeli registry analysis found that locally representative recruitment and targeted expansion could improve projected match opportunities for underrepresented subethnic groups. It was a 2017 modeling study in one national registry, so leaders should not transfer its projected match rates to another population. The operational principle remains important: outreach should be guided by whom the registry needs to serve, conducted with community partners, and evaluated beyond raw enrollment.¹⁹

Support continues after collection. Research with pediatric sibling donors has described complex positive and negative emotions and the need for follow-up that considers the donor as a person, not only as a source of cells. The evidence is older and based on relatively small samples, but it highlights a durable governance question: who remains responsible for the donor’s physical and psychosocial needs when the recipient’s clinical course commands most attention?²⁰

Executive governance should begin with a narrow charter. The purpose is not to combine every donation program under one metric. It is to ensure that public communication, clinical operations, community relationships, and donor support are aligned. A cross-functional group may include executive sponsorship, critical care, emergency services, nursing, transplant or donation coordination, blood-bank or transfusion leadership, laboratory services, ambulatory operations, communications, compliance, privacy, equity, information technology, and patient or community representatives. External partners should participate where responsibilities intersect.

Each pathway needs a clinical owner and an operational owner. The clinical owner maintains evidence-based eligibility, notification, safety, and escalation standards. The operational owner maintains capacity, contact information, scheduling, documentation, and exception resolution. Communications leaders verify that public language matches current practice. Privacy and compliance leaders clarify information transfer, authorization, and disclosure. Quality leaders define denominators and audit whether a recorded completion represents what actually happened.

Workflow design should account for emotional labor. ICU nurses, donation coordinators, collection professionals, navigators, and community-facing staff may carry clinical, ethical, and relational demands that are not visible in throughput measures. Training should include role-play, difficult questions, cultural and spiritual humility, privacy, responding to uncertainty, and escalation. Debriefing should be available after demanding cases without turning family decisions into a staff performance score.

Technology can support, but not replace, accountable relationships. Electronic triggers may reduce missed referral opportunities. Scheduling tools can help donors locate appointments. Registry systems can maintain contact information. Dashboards can surface delays or disparities. Every tool still needs validation, exception handling, access controls, downtime procedures, and a human owner. Automation that sends more people into an unavailable pathway can increase distrust.

Begin with definitions. For organ and tissue donation, specify the eligible or potentially eligible population, clinical trigger, notification interval, authorization opportunity, disposition, and follow-up. For blood and platelets, define eligible contacts, completed appointments, deferrals, reactions, first-time donors, repeat donors, and return interval. For marrow registries, distinguish outreach contact, informed enrollment, current contactability, confirmatory testing, availability, completed donation, and donor support. For living donation, separate inquiry, evaluation, withdrawal, approval, surgery, recovery, and long-term follow-up.

Measures should be interpreted as a set. Faster notification is not success if family communication becomes fragmented. More registry enrollments are not capacity if contactability declines. More appointments are not a safe supply if donor reactions or product discard rise. Higher authorization is not an appropriate target if teams feel pressured to override agency. Balanced review combines reliability, safety, experience, equity, workforce, and clinical appropriateness.

Stratify only when data quality, sample size, and privacy allow. Useful views may include age, language, geography, payer or financial-support need, disability, race and ethnicity, donation type, first-time status, referral source, and time of day. Suppress or aggregate small cells. Pair quantitative differences with qualitative review. The purpose is to identify a correctable barrier, not to label a population.

During the first 30 days, establish the control record. Confirm the accountable executive, clinical and operational owners, applicable partner, current policy, authoritative public destination, eligibility language, handoffs, privacy requirements, and baseline measures. Trace recent cases or donor journeys to locate delays, conflicting information, inaccessible steps, or unresolved questions. Include people with lived experience and frontline staff in the review.

During days 31 through 60, test a narrow improvement. Examples include a revised ICU notification and handoff, a donor-family communication support process, a blood-drive access and adverse-event follow-up standard, or a marrow-registry readiness and contact-update workflow. Train the involved teams with realistic scenarios. Confirm what happens outside normal hours. Use a visible exception log and assign someone to resolve each failed handoff.

During days 61 through 90, compare process reliability, burden, safety, experience, and equity with the baseline. Review cases that did not complete and those that required unusual work. Ask whether the intervention created new pressure, delay, privacy risk, staff burden, or exclusion. Standardize only the parts that performed reliably. A campaign should scale after the route is usable, not before.

• National Donor Day, Donate Life America
• Why Sign Up as an Organ Donor, U.S. Department of Health and Human Services
• Schedule a Blood, Platelet, or Plasma Donation, American Red Cross
• Join the Donor Registry, NMDP